

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in this Application.

1. (Currently amended) A phenolic antioxidant-chromium complex that is therapeutic for treating hyperglycemia, wherein the phenolic antioxidant has no pro-oxidation activity and wherein the phenolic antioxidant is ~~in~~ a purified hydrolyzable tannin fraction of plant origin from Phyllanthus emblica (syn. Emblica officinalis) wherein the chromium is Cr(III) and which prevents Cr(III), which is therapeutic, from getting converted to Cr(VI), which is toxic, and wherein the chromium content in the complex is from 0.01 to 20% of the complex.

2. (Previously presented) The complex of claim 1, wherein the hyperglycemia is due to a diabetic condition.

3. (Canceled).

4. (Canceled).

5. (Canceled).

6. (Canceled).

7. (Currently amended) The complex of claim ~~[[6]]~~1, wherein the chromium content in the complex is from 0.02 to 10%.

8. (Canceled).

9. (Currently amended) The complex of claim 1, wherein the ~~tannin fraction~~ comprises low molecular weight hydrolyzable tannin having ~~has~~ a molecular weight below 2,000.

10. (Canceled).

11. (Canceled).

12. (Canceled).

13. (Currently amended) The complex of claim ~~[[11]]~~1, wherein the hydrolyzable tannin is from the Phyllanthus emblica fruit.

14. (Canceled).

15. (Canceled).

16. (Canceled).

17. (Canceled).
18. (Canceled).
19. (Canceled).
20. (Canceled).
21. (Canceled).
22. (Previously presented) A formulation of the complex of claim 1, and a pharmaceutically or nutritionally acceptable excipient.
23. (Canceled).
24. (Previously presented) The complex of claim 1, further comprising an additional active ingredient.
25. (Previously presented) The complex of claim 24, wherein the additional active ingredient is an antioxidant, vitamin, carnitine, carnosine, N-acetyl-L-cysteine, biotin, polycosanol, aminoguanidine, fatty acid or plant extract, or mixtures thereof.
26. (Previously presented) The complex of claim 7, wherein the chromium content in the complex is from 1 to 8% of the complex.
27. (Previously presented) The complex of claim 1, wherein the molecular weight of the tannin in said tannin fraction is below 1,000.
28. (Withdrawn) A method of treatment for hyperglycemia which comprises administering to a mammal the composition of claim 1.
29. (Withdrawn) The method of claim 28, wherein the hyperglycemia is the result of a diabetic condition.
30. (Previously presented) The formulation of claim 22, wherein the phenolic antioxidant-chromium complex has 10 to 1,000  $\mu\text{g}$  of chromium content.
31. (Canceled).
32. (Canceled).
33. (Canceled).
34. (Previously presented) The complex of claim 1, wherein the phenolic antioxidant-chromium complex has 10 to 1,000  $\mu\text{g}$  of chromium and is combined with a pharmaceutically or nutritionally acceptable excipient.

35. (Withdrawn) The method of claim 28, wherein the composition is administered once or twice a day.

36. (Canceled).

37. (Canceled).

38. (Canceled).